Thank you for your message about Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects. You must verify your email address to receive further communication about this trial. Please check your email for a verification message.
We're sorry, your verification code has expired. Please submit another form using the button below to receive communications about your preferred clinical trial study.
Clinical Trial Study Email Verified Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects